Introduction
============

Rosacea is a characteristic condition affecting skin by causing facial erythema or redness. Around 1 in 10 people in the world are affected by rosacea. It is a chronic, inflammatory disease which is poorly understood due to its intricate reason of cause and onset [@B1]. The disease affects the convexities of central face, firstly by triggering the redness on your nose, followed by cheeks, chin, and forehead, by causing swelling and skin sores that look like acne. It can also cause burning sensation and soreness in the eyes [@B1]-[@B2]. In more severe cases, the skin can become thicker and enlarge on or around the nose and small blood vessels in the facial skin become visible [@B3]. The disease can be triggered by certain psychological factors like stress and exposure to certain environment or allergens [@B4]-[@B5]. Rosacea has resemblances with acne and other skin disorders [@B2]. As with acne, there are some microorganisms that seem to play a role in symptoms. However, it is important to realize that rosacea is not "infectious," and cannot be transmitted from one person to another. From the recent studies it is revealed that people with fair-skin are more prone to rosacea [@B6]. It is more common in women, but the symptoms are often more severe in men. The symptoms tend to recur, usually intermittent but can progressively lead to permanently flushed or red (colour) skin [@B7], as the skin may fail to return to its normal colour and the enlarged blood vessels and pimples arrive in time. The latter may be described as high colour and is associated with the development of permanent telangiectasia [@B8]. Additionally, there are individual reports of facial edemas and gritty eyes. Rosacea may rarely reverse itself and generally lasts for years, and, if untreated, it tends to gradually worsen [@B9].

The onset of the disease could be from childhood or early teen and exacerbates in adulthood due to change in lifestyles, food, psychological factors. The symptoms of rosacea were also reported after excess intake of alcohol but not specific [@B10]. The exact cause and mechanism of pathogenicity is still unknown, all the proposed mechanisms were based on sheer observations or correlations.

Methods
=======

A systematic literature review was conducted of peer-reviewed articles published between 1990 and March 2014 in the following databases: EMBASE, PubMed and the Cochrane Central Register of Controlled Trials (CENTRAL). The following search terms were entered: "rosacea or pathophysiology or randomized controlled trials or controlled trials." Reference lists within individual studies and review papers were screened to retrieve relevant studies. The following general inclusion criteria were applied: (i) Types of study design: RCTs and other (ii) experimental studies. Comparison groups included no treatment or other interventions. We excluded abstracts, dissertations, studies involving trials with post-test only design, trials including pathophysiology intervention as a small component of health promotion programmes, animal studies, studies lacking outcomes related to the objectives of this review as well as non-English articles.

Results
=======

The literature search yielded 5141(n) articles from various databases with 2461 articles from PubMed, 1461 articles from EMBASE, 1000 articles from MEDLINE®. Cochrane CENTRAL was also used for the search of literature, which yielded 209 completed and on-going articles. 10 articles were considered from other sources. The articles left after duplicates are removed and total articles screened are 2680. Applying inclusion and exclusion criteria, 2627 articles were excluded, leaving 53 full-text articles under eligibility criterion. 35 full-text articles were excluded from selected 53, as they do not fit for the literature. 14 full-text research articles were included for high quality synthesis. **Figure [1](#F1){ref-type="fig"}** depicts the flow diagram of selection process. Out of 14 articles, 5 are randomized control trials (RCTs), 2 are controlled trial, 3 comparative trials, 2 observational trials, 1 prospective and 1 diagnostic trial. The 14 studies selected are conducted all over the world, 5 trials are from USA, U.K (with 1 multicenter) and 3 trials are from France, and one each from Ireland, Germany, Croatia, Georgia, Italy and Libya. The sample size from all the studies ranging from n= 20 to n= 504. Included trials have got subjects from young to middle age, which helped us to correlate the occurrence of the disease in different age groups. **Table [1](#T1){ref-type="table"}**describes the detailed description of trials included.

Studies were grouped into two key intervention areas: pathophysiology based on various trigger factors (Sunlight, microorganisms, chemical and food ingested, immune responses) and other based on specific symptoms & sub-types. Within these groups, the quality synthesis of evidence is provided by using a narrative approach. Out of 14 trials, 6 RCTs investigated on various trigger factors and the rest of them are based on the symptoms and sub-types. The study period among selected studies varied from 4 weeks to 12 months. Among all the studies, only one was multicenter study by Casas et al. [@B25] conducted across the USA (n= 98) on Demodex, immune responses in rosacea condition. 3 studies used the surgical procedures, blood samples of the patient to measure the T-cell responses, peroxidase levels and inflammation levels [@B19], [@B32], [@B48]. Only one study was an observational, cross-sectional survey conducted on clinical association and disease progression between rosacea sub-types [@B46]. The adherence rate in all studies was measured, an average of 88% (range: 60 - 100%) of participants were examined till the end of the trials. The studies used different measurement parameters like biopsy specimens immuno-staining, T-cell response from blood samples of patients and HCs, cross-sectional surveys, reactive oxygen species (ROS) measurement by superoxide dismutase (SOD) & glutathione peroxidase (GPX), ferritin levels were measured by serum peroxidases and ant oxidative levels from blood samples [@B36], [@B39], [@B48]. For measuring the presence of the gut bacteria, the patients are lactulose and glucose breath tests [@B67]. In some of the studies, the investigators used the overall assessment of inflammatory lesion severity was expressed as a 7-point static score, ranging from 0 (clear) to 7 (severe), according to an investigator\'s global assessment (GA) [@B39], [@B48], [@B68].

The statistical analysis of the results from all the studies were performed using various versions of SPSS® (11-22), Graph pad prism by analysis of variance (ANOVA), independent t-test, student t-test etc.

Effects of various trigger factors
----------------------------------

Proposed trigger factors are grouped into the following categories based on the various trials performed [@B11]: vasculature, climatic exposures, degeneration of dermal matrix, chemicals and ingested agents, microbial organisms, ferritin levels in body, influence of reactive oxidative species. However, the main reason causing the disease is still unknown. Also the disease progression among the subtypes (erythemato-telangiectatic, papulopustular (PPR), phymatous, and ocular) could be either by a single factor or combination of factors [@B4], [@B15]. Consequently, rosacea-prone persons must have an inherent sensitivity to these ubiquitous triggers [@B12].

### Climatic Exposure

Exposure to harsh climatic conditions damages cutaneous blood vessels and dermal connective tissue [@B13], [@B14]. Facial convexities and flare during rosacea could possibly occur due to exposure to solar irradiation [@B14]. Relation to heat stimuli due to sunlight exposure and rosacea was shown in the study conducted by Guzman-Sanchez et al [@B18].

### Vasculature

Flushing associated with rosacea is possibly caused by increased blood flow to blood vessels which are closer to the surface of the face [@B18]. And also, hyperthermia by vasodilation is thought to be exaggerated in rosacea patients [@B12].

### Degeneration of dermal layers

Rosacea involves in the damage of endothelium and degeneration of the dermal matrix [@B16]. But the facts little known are whether the initial damage is in the dermal matrix and leads to poor tissue support of cutaneous vessels. After which the pooling of serum occurs, possibly giving rise to the inflammatory mediators, and metabolic waste. It could also be like the initial abnormality exists in the cutaneous vasculature [@B15]-[@B17] and followed by vascular leakage and delayed clearance of serum proteins, inflammatory mediators, and metabolic waste, thus resulting in matrix degeneration [@B17].

Perivascular inflammation
-------------------------

An inflammatory penetrate could exist in a perivascular location. The evidence is however conflicting regarding which location predominates [@B19]. For understanding the perivascular inflammation phenomena, more studies need to be designed to categorize subtypes of rosacea depending on the sub-classification.

Foods, therapeutics and other chemical agents
---------------------------------------------

The excessive intake of processed and ready to use food and hot beverages are traditionally thought to trigger flushing in patients with rosacea [@B19]. However, most of the evidence does not support that the dietary factors play a central role in the pathogenesis. And also, specific medications such as anti-arrhythmic drugs (amiodarone) have proven to play a vital role in the disease pathogenicity [@B21]. Apart the drugs, any high intake of useful vitamins such as B-6 and B-12 may cause reddish flares for patients with rosacea [@B10], [@B20]-[@B21].

Microorganism borne
-------------------

Demodex Folliculorum (*Demodex)* mites that normally inhabit human hair follicles may play a vital role in the pathogenesis of rosacea. Some studies suggest that *Demodex* invades the skin regions that are affected in rosacea, such as the nose and cheeks [@B22]. Research also suggests that an immune response of T-cell occurs at the site of *Demodex* antigens in patients with rosacea [@B23]. However, the conflicting evidence indicates that *Demodex* does not induce an inflammatory response in patients with rosacea, as *it* is also found in large numbers of healthy individuals without rosacea [@B24], [@B25]. And also, inconclusive evidence suggests that there is a possible association of Helicobacter*pylori* with the aetiology of rosacea [@B26]. However, many of the studies have not controlled for confounding variables that influence *H. pylori* prevalence, such as age, socioeconomic status, sex and certain medications [@B27], [@B66]. Furthermore, these studies were not statistically significant to account for the ubiquitous nature of *H pylori* and also demodex infection.

Role of Antimicrobial peptides
------------------------------

Antimicrobial peptides (AMPs) have an important role in rosacea pathogenicity. Being the small molecular weight proteins, they are the face of innate immunity. AMPs are proven to show a wide variety of antimicrobial activity against bacteria and virus [@B28], [@B45]. They have been inducted in the pathogenesis of many inflammatory skin diseases as the first line of defence upon injury or infection of the skin [@B46]-[@B47]. The most common types of AMPs are cathelicidins and β-defensins. The evidence based on the recent research shows the high level expression of cathelicidins in individuals affected by rosacea [@B29]-[@B30]. The presence of human cathelicidins, specifically, human cationic antimicrobial protein, hCAP-18/LL-37 has been found in high numbers in rosacea patients. The cathelicidin, hCAP/LL-37 is not only expressed in leukocytes, lymphocytes but also effects vascular endothelial layer by modulating the vascular endothelial growth factor (VEGF) [@B31]-[@B32]. The researchers induced LL-37 and its novel peptides into mice, which gave rise to inflammatory responses, telangiectasia and erythema. This output led researchers postulate that an excess of cathelicidins combining with abnormal processing caused disease [@B34].

Influence of Reactive Oxygen species
------------------------------------

The process of neutrophils releasing the reactive oxygen species (ROS) as an early inflammatory response is postulated to have important role in rosacea [@B35]. ROS leading to oxidative tissue damage is explained by the free radicals such as superoxide anions and hydroxyl radicals, in addition to other reactive molecules, such as molecular oxygen, hydrogen peroxide [@B39], [@B40]. The following are several mechanisms which state how ROS result in skin inflammation (**Figure [2](#F2){ref-type="fig"}**) [@B40]-[@B43]:Inactivation of natural defenses caused by oxidant stress from ROS.Change of the lipid balance in rosacea patients, which in normal proportions would suppress the creation of ROS.The production of cytokines and other inflammatory mediators by keratinocytes, fibroblasts.The endothelial cells damaged by ROS and,The generation of ROS by cathelicidins which are found in greater amounts in the facial skin of affected patients.

Ferritin levels and Oxidative damage
------------------------------------

The Iron levels in body specifically at cellular level should be maintained, as it catalyzes the conversion of hydrogen peroxide to free radicals leading to tissue injury by damaging cellular membranes, more specifically the proteins and DNA. Iron that is not metabolized is stored as ferritin at the cellular level [@B35]. In a recent study, the biopsy specimens of skin from patients with rosacea were immune-histo-chemically analyzed, and the number of ferritin-positive cells was significantly higher in affected individuals compared with control subjects [@B36]. Moreover, the higher ferritin positivity in cells is linked with advanced subtypes of rosacea. And so, we can say that pathogenesis of rosacea is interdependent on free iron release (proteolysis) of ferritin resulting in oxidative damage to the skin [@B37].

What are the ongoing drug trials on Rosacea?
--------------------------------------------

In August 2013, the topical form of the alpha-2 agonist brimonidine [@B44] became the first Food and Drug Association (FDA)-approved topical treatment developed and indicated specifically for rosacea-associated facial erythema. The medication, which was approved for adults aged 18 years or older, was assessed using 2 phase 3 clinical studies (short-term), involving a total of 550 patients, as well as a long-term study (up to 12 months) in 276 subjects [@B44]. The most common adverse events (i.e., those affecting at least 4% of patients) in the long-term trial included flushing (10%), erythema (8%), rosacea (5%), nasopharyngitis (5%), skin burning sensation (4%), increased intraocular pressure (4%), and headache (4%).

Furthermore, the treatment gap will soon be narrowed, thanks to the development of novel therapies that are specifically designed to address the problem of redness. In addition, other agents in the pipeline should further improve the arsenal of treatments for the papules and pustules of rosacea.

In the year 2013, many new therapies are currently in various clinical evaluation phases (**Table [2](#T2){ref-type="table"}**) for the treatment of patients with rosacea and a few more are in preclinical and laboratory testing stage. The novel compounds are expected to provide clinically improvements in the treatment of patients with rosacea the papulopustular, erythemato-telangiectatic types, thereby bridging the gap by addressing the erythema component of rosacea, where current approaches fall short.

Furthermore, American academy of Dermatologists (AAD) in 2013 proposed the use of probiotics in treating rosacea [@B66]. The hypothesis was based on "Bacterial interferences." The probiotics, with living microorganisms are known for their positive effects. When applied topically on rosacea or acne prone area of skin (site), the immune system recognizes them as foreign particle and acts at site, thus reducing inflammation, redness, or bumps. And also, a couple of small-scale trials one conducted in Korea and other in Italy, showed promising results in effective clearing of rosacea and acne symptoms [@B67]-[@B68].

Discussion
==========

This review identified 14 key studies (**Table [1](#T1){ref-type="table"}**) on different pathophysiologies of rosacea. Apart from randomized control trials, there were comparative, observational, diagnostic trials were included. No adverse events were reported from any of the study; however confirmation of specific or exact single cause for the disease was a limitation of the review. Each cause identified here could possibly act as precursors, a bridge between and amongst all the caused.

Firstly, exposure to sunlight could trigger the disease to the people whose skin is too sensitive and prone to rosacea. Guzman-Sanchez et al [@B18] in a comparative (n= 24), multicenter, cross-sectional trial conducted in USA for over a year to assess the heat pain threshold and dermal vascularity with 8 healthy controls (HCs) and 16 rosacea patients. This study showed enhanced sensitivity to noxious heat stimuli in rosacea-affected skin, which was more prominent in the PPR group (*P*\< .05). By this study, it can be said that there is a correlation between heat and vascularity in rosacea.

Cribier et al. [@B19] conducted a diagnostic trial in France among patients & HCs (n= 86), on relation vascularity and inflammation. The study revealed that vasculature and inflammatory responses are interrelated and aiding in pathology of rosacea. The result of excess of blood supply leads to hyper-erythema.

In 2006, Smith et al. [@B50] conducted a trial to study the vascular endothelial growth factor (VEGF) expression levels in rosacea patients (vascular endothelium and mononuclear blood cells). All the patients (n= 20) were diagnosed with rosacea, the biopsy specimens were collected and immuno-stained to identify the expressions of VEGF, VEGF-R1, VEGF-R2 using indirect method using antigen retrieval. The VEGF-R1, R2 receptors frequently stained positive but infrequently in case of VEGF. And in case of lymphocytes, macrophages and plasma cells, all three receptors are very well expressed (*P*= 0.005). VEGF receptors-binding-ligands may contribute in vascular and cellular changes in the rosacea patients. In comparison with the studies conducted by Guzman-Sanchez et al [@B18] and Cribier et al. [@B19] with Smith et al, there is surely a connection between vasculature, inflammation, immune responses and rosacea.

In a study conducted by LE Heuzey et al. [@B21] to assess the effects of chemical agents on skin redness/flush, it was evident that external agents have a role in pathophysiology of rosacea. Here, dronedarone and amiodarone (antiarrhythmic agents) were checked on rosacea patients/HCs. There was a significant rise in the redness/flush (n=504, *P*= 0.129) on the skin and thus it contributes to rosacea. Though there is no significant evidence that food items aid in disease, however it cannot be ruled out.

The potential role of ROS was measured by Bakar et al [@B39]. The study is an unprecedented ex vivo study (n= 42) to support the role of ROS in rosacea. The ROS levels when compared to HCs were much higher in rosacea patients. Ferritin levels, oxidative damage in rosacea were measured by Tisma et al [@B36]. The RCT was conducted (n= 71, HC= 11) using the blood samples and measuring the serum peroxidases and serum antioxidative potential levels. The serum peroxidase levels were significantly higher in the rosacea patients, which helps in release free iron ions and increase the oxidative stress and ferritin expression.

Cathelicidin levels in rosacea patients were higher than HCs in study conducted by Coda et al [@B32]. The study (n= 55, HC= 5) measured the serine protease activity and correlated the levels of the cathelicidin levels. Rosacea can be averted in the early stages was shown in the trial conducted by Tsiskarishvili et al [@B49]. The observational study (n= 50) conducted on beta-blockers and rozaliak in early stage rosacea condition. Both beta-blockers and rozaliak had a positive effect in rosacea treatment during the early stage diagnosis.

The potential role of microorganisms in pathophysiology of rosacea is still a debate. However, the various studies conducted on possible role of Demodex and H. Pylori in rosacea were scientifically significant. Jarmuda et al. [@B25] conducted a controlled trial (n= 127) to measure the level of demodex mites on facial skin. All the skin samples were collected from patients, HCs and checked the presence of demodex. The percentage of demodex mites in rosacea patients was much higher when compared to HCs. A similar result was obtained in another study conducted by Casas et al [@B24]. The demodex levels in rosacea patients (n= 98) in correlation to their immune responses were measured. The density of demodex in rosacea patients was 5.7 times higher than HCs (*P*= 0.05).

With regards to H. Pylori, many studies were conducted to assess the role in rosacea. All the studies were nor inconclusive nor affirming the role of H. Pylori in rosacea. Sherif et al [@B28] conducted a RCT (n= 36) on relation of sunlight on H. Pylori in rosacea. Here, exposure to sunlight, vasculature and inflammatory response acts as a trigger point to gut bacteria stimulating rosacea. The role of bacteria is still unknown. However, in another study randomized trial conducted by Parodi et al. [@B66] demonstrated that there is highly significant number of H. Pylori in the gut of the rosacea patients (n= 53) when compared to HCs (n= 60) (*P*\< 0.001). Eradication of small intestinal bacterial overgrowth state and normalization of the intestinal flora via the antibiotic rifaximin led to improvement of rosacea.

Brown et al. [@B48] conducted a comparative trial (n= 57) between rosacea and cutaneous Lupus erythematosus (LE) to measure the chronic immune activation phenomena. Chronic immune activation leads to mild-severe inflammations giving rise to severe skin disorders. In this study the role of T-cells (acquired immune subsets) was assessed. Interestingly, the T-cell mediated responses have a significant role in rosacea and LE conditions. Thus, we can say immune responses are responsible for disease with vasculature.

The rosacea progression was also associated with sub-types. Tan J et al. [@B46] conducted an observational, cross sectional survey amongst patients (n= 135) who are diagnosed with different types of rosacea. The clinical association and progression of rosacea amongst the various sub-types was evident (*P*= 0.005).

Rosacea, the most intricate disease, has multiple pathologies involving prominent vascular and inflammatory response factors. Characteristic small blood vessels, mononuclear blood cells, perivascular inflammation come into account of histology. Various environmental triggers involving exposure to sunlight, temperature change have a prominent role in the disease. The role of microorganisms was explained with weight of evidence. **Figure [3](#F3){ref-type="fig"}** explains the whole pathophysiology, how each factor singly or cumulatively responsible for disease.

Demodex mites presence stimulates the inflammatory response with help of bacteria degradation in the body. Any alteration or abnormality in vascular system, leads to dilation of blood vessels which happens to be a favorable conditions for demodex to colonize and thrive. The presence of high number demodex mites leads to activation of various inflammatory responses resulting in appearing of initial symptoms of the disease. The chronic inflammatory responses in turn help in release of oxygen free radicals leading to dermal matrix damage and blood vessel damage. The release of oxygen free radicals, blood vessel damage and additional inflammatory responses can possibly result in over expression of pro-inflammatory peptides such as cathelicidins. Apart from the mentioned factors, psychological factors such as stress, anxiety and depression can also be responsible for rosacea. The psychological factors either alone or in combination with the consumption of processed comfort foods alters the gastrointestinal flora, which in turn leads to increased intestinal permeability.

Conclusion
==========

In conclusion, we can say that there are multiple factors responsible for the disease. All the present treatment options and forthcoming therapies are based on symptoms. There is still need for high quality RCTs targeting clinical, cellular and molecular pathophysiological relations to rosacea. Future trials should address methodological limitations, including sample size, recruitment and adherence as well as detailed characterization of clinical disease correlation in rosacea condition and duration.
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![The presumed pathophysiology of rosacea in correlation with specific molecular, immunological, neuronal and clinical triggers. (A) Recurrent exposure to extreme sunlight (environmental changes) causes the dermal matrix degeneration, which in turn may trigger genetic predisposition leading to hypersensitivity and flush on the skin. (B) As a part of hypersensitivity, it triggers the innate immune response. (C) Effect of microorganisms like Demodex and Helicobacter pylori gives rise to the several inflammatory responses in the body. (D) Chemical and food agents would also trigger inflammatory responses. (E) Vasodilation of blood vessels by immune responses that may lead to Telangiectasia, Erythema. (F) Neural activation results in vasodilatation, edema and burning sensation (G) Chronic neurogenic inflammation may lead to persistent erythema, followed by angiogenesis. (H) Imbalance in lymphatic system leads to lymphedema followed (I) Glandular hyperplasia and fibrosis (J) leading to inflammatory responses like vasodilation, extravasation and plasma leakage (severe case) giving rise to (K) erythema, edema and papules.](ijmsv12p0387g003){#F3}

###### 

Detailed description of trials

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author              Trial type                                                                       Sample size & description                           Length      Outcome/Result
  ------------------- -------------------------------------------------------------------------------- --------------------------------------------------- ----------- -----------------------------------------------------------------------------------------------------------------------------
  Jarmuda et al\      Controlled trial on Demodex levels on face of patients                           n= 127, R= 75, HC= 52                               15 weeks    Demodex ↑ in patients (P = 0.0001)
  (Ireland)\                                                                                                                                                           
  [@B25]                                                                                                                                                               

  Sherif et al\       Randomized controlled trial on H. pylori                                         n= 36, Mean age ± SD = 37.8 ± 6.6 years             21 weeks    Sun exposure and H. Pylori have possibly have role in Rosacea. (*P*= 0.005)
  (Libya)\                                                                                                                                                             
  [@B27]                                                                                                                                                               

  Brown et al\        Comparative analysis (Rosacea (R) & Cutaneous Lupuserythematous (LE))            n= 57, R= 27; LE=30\                                6 months    T-Cell mediated responses have significant role in R and LE.
  (USA)\                                                                                               Average age=\                                                   
  [@B48]                                                                                               (55.5 vs 42.3 years\                                            
                                                                                                       *P* = .0029)                                                    

  Tisma et al.\       Randomized controlled trial on serum peroxides & ferritin levels                 n= 71, R= 60; HC= 11\                               6 months    Serum peroxides ↑ & serum total anti-oxidative potential levels ↓ in R v\'s HC (*P*= .05)
  (Croatia)\                                                                                           Mean age= 30 to 70 years                                        
  [@B36]                                                                                                                                                               

  Bakar et al.\       Controlled trials on ROS levels                                                  n= 42, R= 17, HC= 25\                               6 weeks     ROS levels ↑ in rosacea patients than in HC
  (Turkey)\                                                                                            Mean ± SD age 50.3 ±19, 15.1 years.                             
  [@B39]                                                                                                                                                               

  Cribier et al.\     Diagnostic trial on Pathophysiology of Rosacea                                   n= 86\                                              3 months    Vasculature and Inflammation primary factors in Rosacea
  (France)\                                                                                            mean age= 25 to 49 years                                        
  [@B19]                                                                                                                                                               

  LE Heuzey et al.\   Randomized controlled trial on Amiodarone on skin (redness/flush)                n= 504, CI = 95%\                                   12 months   HR = 0.80; 95%\
  (France)\                                                                                            Middle-aged patients                                            CI 0.60-1.07; P = 0.129\
  [@B21]                                                                                                                                                               Redness ↑

  Tsiskarishvili\     Observational trial on early stage treatment                                     n= 50, R= 25, HC= 25,\                              12 months   Beta-blockers and Rozaliak\
  et al.\                                                                                              mean age= 25 to 49 years                                        effective for treatment
  (Georgia)\                                                                                                                                                           
  [@B49]                                                                                                                                                               

  Tan J et al.\       Observational cross-sectional survey on clinical association &\                  n (R) = 135                                         3 months    Disease progression amongst associated sub-types. (*P* = 0.005)
  (Germany)\          progression b/w sub-types                                                                                                                        
  [@B46]                                                                                                                                                               

  Guzman-Sanchez\     Comparative trial to assess heat pain thresholds and skin blood flow             n= 24, R= 16;\                                      5 weeks     Enhanced sensitivity to\
  et al.\                                                                                              HC= 8                                                           noxious heat stimuli/blood\
  (USA)\                                                                                                                                                               flow in rosacea-affected skin.\
  [@B18]                                                                                                                                                               *P*\< .05.

  Casas et al.\       Prospective/multicenter trial on Demodex, Rosacea & immune responses.            n= 98, R= 50\                                       12 months   D. folliculorum density was\
  (France)\                                                                                            HC= 48                                                          5.7 times ↑ in rosacea patients\
  [@B24]                                                                                                                                                               than in healthy volunteers.\
                                                                                                                                                                       *P* \< 0.05.

  Smith et al.\       Controlled trial on vascular endothelial receptor (VEGF) expression in rosacea   n= 20 (R)\                                          4 weeks     VEGF-ligand binding in rosacea could contribute\
  (USA)\                                                                                               Mean age= 25 - 35 years                                         vascular & cellular changes
  [@B50]                                                                                                                                                               

  Coda et al.\        Randomized multicenter on role of cathelicidin in rosacea                        n= 60 (R= 55)\                                      16 weeks    Cathelicidin ↑ & serine protease activity ↑ in rosacea patients.
  (USA, U.K)\                                                                                          HC= 5\                                                          
  [@B32]                                                                                               age= 18-40 years                                                

  Parodi et al.\      Randomized Controlled trial on gut bacteria                                      n= 113 (R= 53), mean age, 52 ± 15 years.\           9 months    Gut bacteria ↑ in rosacea patients when compared to HCs. Rifaximin drug therapy was given to rosacea patients and disease ↓
  (Italy)\                                                                                             HC= 60 mean age, 49 ± 11 years; 82 women, 31 men.               
  [@B66]                                                                                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**N=**Total number of patients; **R**= Rosacea; **HC**= Healthy control; **HR**= hazard ratio; **P=**Significance; **CI** = confidence interval; ↑ = High; ↓ = Low.

###### 

List of drugs under trials

  Type                               Investigational Drug            Intended Actions                                  Clinical trial phase   Dosage form             References
  ---------------------------------- ------------------------------- ------------------------------------------------- ---------------------- ----------------------- ----------------
  Erythematotelangiectatic rosacea   Laropiprant                     Human prostaglandin D2 receptor-1                 Early phase            Topical                 [@B52]
                                                                                                                       (On hold)                                      
                                     Aganirsen                       Antisense oligonucleotide                         Early phase            Topical                 [@B53]
  Papulopustular rosacea             Omiganan pentahydrochloride     Disruption of the cytoplasmic membranes           Phase III              Topical                 [@B60], [@B61]
                                     Ivermectin 1% cream             -n/a-                                             Phase III completed    Topical                 [@B55]
                                     Carbamide peroxide              Inhibiting inflammatory mediators                 Phase III completed    Topical                 [@B62]
                                     SGT-VD-54                       -n/a-                                             Phase II               Topical                 [@B62]
                                     Sarecycline hydrochloride       Down regulates inflammatory cytokine production   Phase II               Oral                    [@B63]
                                     Apremilast                      Modulates multiple anti-inflammatory pathways     Phase II completed     Oral                    [@B56]
                                     Azelaic acid foam                                                                 Phase III ongoing      Topical Author et. al   [@B57]
                                     Incobotulinumtoxin A            -n/a-                                             Phase II               I.V                     [@B58], [@B64]
  Phymatous Rosacea                  No specific drug under trials   -n/a                                                                                             
  Ocular Rosacea                     No specific drug under trials   -n/a-                                                                                            

-n/a- = Not available; I.V= Intravenous.
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